The invention regards the use of triiodothyronine sulfate, commonly named T 3 S , as a medicament having thyromimetic activity for the treatment of pathologies due to organic deficiency of triiodothyronine ( T 3 ), as such or in association with thyroxine ( T 4 ), and pharmaceutical formulations thereof.